Comparison of Cervical Pathologies in the Presence of High Risk Hpv Positivity

Study Overview
=================
Brief Summary
-----------------
The only malignancy screening test among gynecological cancers is cervical cancer. Cytology examination and Hpv typing with smear are used as screening tests. Hpv positivity is detected in more than 90% of cervical cancers. However, only the Hpv 16-18 type positive patients undergo colposcopy in the routine screening program. Patients with Smear negative, Type 16-18 high-risk Hpv positivity are evaluated by quota after 1 year. the authors performed colposcopy with this study; authors aimed to compare the results of patients with type 16-18 Hpv positivity and type 16-18 high-risk Hpv positivity and to find out whether there was any difference between them. In this way, other high-risk Hpv types other than type 16-18 (31,33,35,45,51, etc.) may be exposed to premalign cervical lesions and possible cancer in a number of earlier and earlier periods by performing colposcopic examination instead of expecting to perform quota after 1 year. we aimed to remove.

Official Title
-----------------
Comparison of Cervical Pathologies in the Presence of High Risk Hpv Positivity in Normal Women With Cytology

Conditions
-----------------
Human Papilloma Virus, Cervical Neoplasm

Intervention / Treatment
-----------------
* Diagnostic Test: colposcopy and colposcopic biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20-65 years old patients with normal smear Exclusion Criteria: Patients with invasive cervical cancer, HIV-positive patients, ASCUS and more risky premalignant lesions in cytology, Over the age of 65 and Patients under 20 years of age, patients with another known gynecological malignancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Genotype of HR-HPV 16/18<br>Patients with genotype of HR-HPV 16/18 who underwent cervical biopsy with colposcopy | Diagnostic Test: colposcopy and colposcopic biopsy<br>* high-risk hpv positivity and colposcopy and cervical biopsy results will be evaluated. thus, it will be defined whether colposcopy will be performed routinely at high-risk hpv.<br>|
| Genotype of HR-HPV Non-16/18<br>Patients with genotype of HR-HPV non-16/18 who underwent cervical biopsy with colposcopy | Diagnostic Test: colposcopy and colposcopic biopsy<br>* high-risk hpv positivity and colposcopy and cervical biopsy results will be evaluated. thus, it will be defined whether colposcopy will be performed routinely at high-risk hpv.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genotype of HR-HPV 16/18 | Results of colposcopies and retrieved colposcopic biopsy of patients with Genotype of HR-HPV 16/18 | 1 MONTH | 
| Genotype of HR-HPV non 16/18 | Results of colposcopies and retrieved colposcopic biopsy of patients with Genotype of HR-HPV non 16/18 | 1 MONTH | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colposcopy, High Risk HPV